The combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib showed an overall response rate of 69% in patients with BRAF V600E-mutated anaplastic thyroid cancer [24]. The gene discussed is MAP2K7; the disease is thyroid gland undifferentiated (anaplastic) carcinoma.